Quarterly ResultJun 22, 2026, 09:07 AM
INVO Fertility Q1 Net Loss $(5.54)M; Going Concern Doubt Raised
AI Summary
INVO Fertility, Inc. reported a net loss of $(5.54) million for Q1 2026 from continuing operations, a significant increase from $(1.49) million in Q1 2025. Total revenue grew by 23.09% to $2.02 million. The company's financial statements include a going concern warning, citing dependence on external financing to meet liquidity needs. Despite this, cash and cash equivalents increased to $4.90 million, partly due to $7.1 million from a warrant inducement. The company continues to focus on its fertility business, including clinic operations and INVOcell technology sales, after divesting most of NAYA Therapeutics in Q2 2025.
Key Highlights
- Net loss from continuing operations increased to $(5.54) million in Q1 2026 from $(1.49) million in Q1 2025.
- Total revenue rose 23.09% to $2.02 million in Q1 2026, with clinic revenue up 22.24% to $1.98 million.
- The company's financial statements include a going concern warning due to liquidity needs.
- Cash and cash equivalents increased to $4.90 million as of March 31, 2026, from $2.08 million at year-end 2025.
- Received $7.1 million in net proceeds from a warrant inducement during Q1 2026.
- Net cash used in operating activities decreased by 45.94% to $(1.92) million in Q1 2026.
- Total liabilities decreased by 25.88% to $9.63 million as of March 31, 2026.
- Divested 80.1% of NAYA Therapeutics in Q2 2025 to focus exclusively on the fertility market.
Price Impact
More from IVF